Hu Shengda, Yan Gaoliang, Xu Hongzeng, He Wei, Liu Zhiyong, Ma Genshan
Department of Cardiology, Zhongda Hospital, Medical School, Southeast University.
Circ J. 2014;78(3):724-31. doi: 10.1253/circj.cj-13-0841. Epub 2014 Jan 8.
Stem cells transplanted to the ischemic myocardium usually encounter massive cell death within a few days after transplantation, and hypoxic preconditioning (HPC) is currently used as a strategy to prepare stem cells for increased survival and engraftment in the heart. The purpose of this study is to determine whether Pim-1 kinase mediates any beneficial effects of HPC for human cardiac progenitor cells (CPCs).
Human CPCs were isolated from an adult heart auricle and were purified by magnetic-activated cell sorting using c-kit magnetic beads; they were hypoxic preconditioned for 6h. Both Pim-1 and p-Akt were determined. CPCs were assigned to one of the following groups: (1) control (without HPC); (2) HPC; or (3) HPC+I (Pim-1 inhibitor). HPC can promote the survival of CPCs. HPC enhances the expression of Pim-1 kinase in a time-dependent manner, which causes a reduction of proapoptotic elements (cytochrome c and cleaved caspase-3) and the preservation/modulation of important components of the mitochondria (Bcl-2, Bcl-XL and p-Bad), and attenuates mitochondrial damages. All of these protective effects were blocked by a Pim-1 inhibitor.
Pim-1 plays a pivotal role in the protective effect of HPC for CPCs, and the promotion of the expression of Pim-1 in CPCs can as serve part of molecular therapeutic interventional strategies in the treatment of cardiomyopathy damage by blunting CPC death.
移植到缺血心肌的干细胞通常在移植后几天内会遭遇大量细胞死亡,目前缺氧预处理(HPC)被用作一种策略来使干细胞为在心脏中提高存活率和植入率做好准备。本研究的目的是确定Pim-1激酶是否介导HPC对人心脏祖细胞(CPCs)的任何有益作用。
从成人心脏心耳中分离出人CPCs,并使用c-kit磁珠通过磁激活细胞分选进行纯化;对其进行6小时的缺氧预处理。检测了Pim-1和p-Akt。将CPCs分为以下几组之一:(1)对照组(无HPC);(2)HPC组;或(3)HPC+I组(Pim-1抑制剂)。HPC可促进CPCs的存活。HPC以时间依赖性方式增强Pim-1激酶的表达,这导致促凋亡元件(细胞色素c和裂解的半胱天冬酶-3)减少,线粒体重要成分(Bcl-2、Bcl-XL和p-Bad)得以保留/调节,并减轻线粒体损伤。所有这些保护作用均被Pim-1抑制剂阻断。
Pim-1在HPC对CPCs的保护作用中起关键作用,促进CPCs中Pim-1的表达可作为通过减少CPCs死亡来治疗心肌病损伤的分子治疗干预策略的一部分。